Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q3 FY2026 Earnings Presentation
27 slides from Concord Biotech's earnings presentation, Feb 11, 2026
Slide 1: Stock exchange cover letter for investor presentation
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com --------------------------------------------------------
Slide 2: Concord Biotech Limited Investor Presentation – February 2026
CONCORD BIOTECH Concord Biotech Limited Investor Presentation – February 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q3 & 9MFY26 Key Financial Highlights
Q3 & 9MFY26 Key Financial Highlights
Slide 5: Q3 & 9MFY26 Key Highlights
Q3 & 9MFY26 Key Highlights Received WHO GMP certificate Received WHO-GMP certification for our Injectable facility (unit 4), enabling entry into the domestic 1 for our Injectable Plant Indian market through own-brand products and Contract Development opportunities. Successful setup of Successfully e
Slide 6: Q3 & 9MFY26 Consolidated Financial Highlights
Q3 & 9MFY26 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) 770.2 315.9 231.3 728.8 248.9 170.8 244.2 277.8 98.0 99.0 75.9 63.7 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Gross Profit Margin (%) EBIDTA Margin (%) PA
Slide 7: Q3 & 9MFY26 Segment wise Revenue Split
Q3 & 9MFY26 Segment wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 577.7 565.0 192.5 770.2 728.8 163.8 219.4 67.6 277.8 176.7 58.4 244.2 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 API : Formulation API
Slide 8: Q3 & 9MFY26 Geography wise Revenue Split
Q3 & 9MFY26 Geography wise Revenue Split Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 422.4 347.8 333.8 770.2 395.0 728.8 148.0 114.1 129.7 277.8 130.1 244.2 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Q3FY25 Q3FY26 9MFY25 9MFY26 Domestic : Export
Slide 9: Management Commentary
Management Commentary Commenting on the Q3 & 9MFY26 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, Revenue for Q3FY26 grew by 14%, driven primarily by strong performance in the API segment. Following receipt of written c
Slide 10: Q3 & 9MFY26 Consolidated Profit & Loss Account
Q3 & 9MFY26 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q3FY26 Q3FY25 YoY Q2FY26 Q-o-Q 9MFY26 9MFY25 YoY Revenue from Operations 278 244 14% 247 12% 729 770 -5% Cost of Goods Sold 66 52 49 160 177 Gross Profit 212 192 11% 198 7% 569 593 -4% Gross Profit Margin 76.3% 78.5% 80.2% 7
Slide 11: Company Overview
Company Overview
Slide 12: Concord Biotech at a Glance
Concord Biotech at a Glance Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Key Highlights Expertise in ✓ Expertise in fermentation-based API manufacturing wit
Slide 13: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Fermentation Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Mission Focus Dedicated to deliver high-quality product that enhance human health,
Slide 14: API Business Overview
API Business Overview API Overview One of the leading global developers and Focus on Niche Fermentation API’s with Diversified Product Portfolio of API’s including manufacturers of Fermentation-based APIs backward integration to Key Starting Material Immuno-suppressant, Oncology, Anti- Infectives &
Slide 15: Formulation Business Overview
Formulation Business Overview Formulation Overview Commercialization of Formulations business in Operate through B2B model across regulated Oral Solid Dosages (tablets, capsules and oral suspension) 2016 to capitalize on the benefits of backward and emerging markets Injectables (Liquid Vials, Dry Po
Slide 16: Trusted CDMO partner for Fermentation & Semi-Synthetic API's
Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Prioritizes innovation, backed by a DSIR- Expertise in fermentation technology and strong Provide contract research and manufacturing R&D infrastructure enable us to undertake complex certified R&D facility with a team of 180
Slide 17: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat FY2000 Operations commenced FY2016 Operations commenced 112302 sq.m. Spread across 94826 sq.m. Spread across 450 m3 Installed capacity 802Mn Units Installed capacity Unit I
Slide 18: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D Initiatives: State-of-the-Art Facilities: Where Ideas Materialise 180 7/5 R&D Employee Approved ANDA/ API R&DLab Strength Finished Products Cost Improvement • Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as w
Slide 19: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Immuno- Mycophenolate Sodium ✓ ✓ ✓ ✓ Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓
Slide 20: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolic Acid DR Tablets USP Mycophenolate Mofetil Suspension My
Slide 21: Diversified Customer Base
Diversified Customer Base New Customer Addition / Product Addition in Existing Customers 118 95 63 47 FY22 FY23 FY24 FY25 Reducing Customer Concentration % Contribution from Top 10 Customers 35.8% FY25 70+ Countries 42.0% FY24 FY23 44.3% Worldwide Presence Tailored Distribution Models 47.7% FY22 250
Slide 22: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Management Global Green Leadership Constant Improvement & Adaptation Environmental Conservation Awarded Bronze Medal by EcoVadis Our Initiati
Slide 23: Key Business Differentiators
Key Business Differentiators
Slide 24: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform Leadership Position 1250 M3 Leadership position for select molecules Fermentation Capacity across two in global markets API facilities R&D Patents 01 02 03 04 Key Starting Material API Manufacturing Over 2 Decad
Slide 25: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Significant Capital Intensive Operational Complex Process & Infrastructural Requirements Long gestation Period Entry Barriers Technical Expertise Requirements (large scale fermenters) Complex technical capabilities, difficulties in scaling up operations and
Slide 26: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing APIs Increasing wallet share Portfolio to new customers with existing customers 01 Formulations Business CONCORD BIOTECH Expanding portfolio through own development & in- Launching new dosage forms including Expanding geographic reach
Slide 27: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com Mr. Sagar Shroff / Mr. Vatsal Sh